Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CAMBRIDGE, Mass., Oct. 04, 2017 -- GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced the appointment of Robert J. Wills, Ph.D. to the Company's Board of Directors. Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business development and alliance management for major pharmaceutical firms and more recently in board roles for small biotechnology companies. Dr. Wills has been a Senior Advisor to the company since June 2015.
Dr. Wills is currently serving in board roles for GTx, Inc; Cymabay Therapeutics, Inc and Parion Sciences. Prior to that, Dr. Wills spent 25-years at Johnson & Johnson in a variety of senior roles in R&D and business development. Dr. Wills also worked ten-years in pharmaceutical drug development at Hoffmann-LaRoche.
"We are very pleased to have Rob join GO's Board of Directors," said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics. "As we chart GO’s growth path, we will benefit greatly from Rob’s ongoing board experience, extensive business development and R&D experience.”
Dr. Wills added, "GO Therapeutics is an exciting company that has an opportunity to play an important role in the advancement of bispecific antibodies for T cell-redirection therapy, antibody-drug conjugates, and immune-based cell therapies. I look forward to transitioning to a board role and working closely with the GO Therapeutics team to help achieve their strategic vision for the company.”
About GO Therapeutics
GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA. For more information please visit www.gotherapeutics.com.
Constantine Theodoropulos 617-816-4637
